Show simple item record

dc.contributor.authorArnadottir, M
dc.contributor.authorDallongeville, J
dc.contributor.authorNilsson-Ehle, P
dc.contributor.authorBerg, AL
dc.date.accessioned2008-07-29T11:40:37Z
dc.date.available2008-07-29T11:40:37Z
dc.date.issued2001-07-01
dc.date.submitted2008-07-29
dc.identifier.citationScand. J. Clin. Lab. Invest. 2001, 61(4):301-6en
dc.identifier.issn0036-5513
dc.identifier.pmid11465344
dc.identifier.urihttp://hdl.handle.net/2336/33574
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractTreatment with adrenocorticotrophic hormone (ACTH) has a well-documented cholesterol-lowering effect. Increased uptake of low-density lipoprotein (LDL) by HepG2 cells in response to incubation with ACTH has been demonstrated but the precise cholesterol-lowering mechanism has resisted elucidation. Since apolipoproteins are important determinants of lipoprotein metabolism, we sought to extend the knowledge of the effect of ACTH treatment on the serum apolipoprotein (apo) pattern. Twelve healthy individuals and 14 dyslipoproteinemic hemodialysis patients were recruited. The two groups responded similarly to ACTH1-24 at the dose of 1 mg daily for four days. In accordance with previous results, serum concentrations of total cholesterol decreased by 18% and 17%, LDL cholesterol by 25% and 30%, and apo B by 20% and 19%, respectively, while there were no significant changes in the serum concentrations of triglycerides, high-density lipoprotein cholesterol and apo AI. Novel findings were that the serum concentrations of total apo E increased by 48% and 31%, and apo B-associated apo E by 69% and 46%, respectively. Moreover, in the healthy individuals, the serum concentrations of apo CIII did not change in response to ACTH, whereas in the hemodialysis patients, those of apo CIII not associated with apo B increased significantly by 44%. Since apo E binds strongly to the LDL receptor, the present results suggest that the cholesterol-lowering effect of ACTH may be mediated by facilitated hepatic uptake of apo E-enriched apo B-containing lipoproteins. Thus, the findings stimulate further research.
dc.language.isoenen
dc.publisherTaylor & Francis Health Sciencesen
dc.relation.urlhttp://www.ingentaconnect.com/content/apl/scli/2001/00000061/00000004/art00007en
dc.subject.meshAdrenocorticotropic Hormoneen
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshApolipoprotein C-IIIen
dc.subject.meshApolipoproteins Aen
dc.subject.meshApolipoproteins Ben
dc.subject.meshApolipoproteins Cen
dc.subject.meshApolipoproteins Een
dc.subject.meshCholesterol, HDLen
dc.subject.meshCholesterol, LDLen
dc.subject.meshHumansen
dc.subject.meshKidney Failure, Chronicen
dc.subject.meshMiddle Ageden
dc.subject.meshRenal Dialysisen
dc.subject.meshTriglyceridesen
dc.titleEffects of short-term treatment with corticotropin on the serum apolipoprotein patternen
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, National University Hospital, Reykjavik, Iceland. margreta@rsp.isen
dc.identifier.journalScandinavian journal of clinical and laboratory investigationen
html.description.abstractTreatment with adrenocorticotrophic hormone (ACTH) has a well-documented cholesterol-lowering effect. Increased uptake of low-density lipoprotein (LDL) by HepG2 cells in response to incubation with ACTH has been demonstrated but the precise cholesterol-lowering mechanism has resisted elucidation. Since apolipoproteins are important determinants of lipoprotein metabolism, we sought to extend the knowledge of the effect of ACTH treatment on the serum apolipoprotein (apo) pattern. Twelve healthy individuals and 14 dyslipoproteinemic hemodialysis patients were recruited. The two groups responded similarly to ACTH1-24 at the dose of 1 mg daily for four days. In accordance with previous results, serum concentrations of total cholesterol decreased by 18% and 17%, LDL cholesterol by 25% and 30%, and apo B by 20% and 19%, respectively, while there were no significant changes in the serum concentrations of triglycerides, high-density lipoprotein cholesterol and apo AI. Novel findings were that the serum concentrations of total apo E increased by 48% and 31%, and apo B-associated apo E by 69% and 46%, respectively. Moreover, in the healthy individuals, the serum concentrations of apo CIII did not change in response to ACTH, whereas in the hemodialysis patients, those of apo CIII not associated with apo B increased significantly by 44%. Since apo E binds strongly to the LDL receptor, the present results suggest that the cholesterol-lowering effect of ACTH may be mediated by facilitated hepatic uptake of apo E-enriched apo B-containing lipoproteins. Thus, the findings stimulate further research.


This item appears in the following Collection(s)

Show simple item record